S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
Log in
NASDAQ:CDXS

Codexis Stock Forecast, Price & News

$19.51
-0.50 (-2.50 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$18.28
Now: $19.51
$20.45
50-Day Range
$20.01
MA: $25.07
$28.80
52-Week Range
$8.43
Now: $19.51
$29.56
Volume1.02 million shs
Average Volume724,620 shs
Market Capitalization$1.16 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.17
Codexis, Inc. discovers, develops, and sells protein catalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.
Codexis logo

Headlines

Codexis: Q4 Earnings Insights - Yahoo Finance
February 26, 2021 |  finance.yahoo.com
Codexis: Q4 Earnings Insights
February 25, 2021 |  finance.yahoo.com
Codexis, Inc. to Host Earnings Call - Yahoo Finance
February 25, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Industrial organic chemicals
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CDXS
CUSIP19200510
Phone650-421-8100
Employees161
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$68.46 million
Book Value$1.80 per share

Profitability

Net Income$-11,940,000.00

Miscellaneous

Market Cap$1.16 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.51 out of 5 stars

Medical Sector

479th out of 1,972 stocks

Industrial Organic Chemicals Industry

12th out of 38 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$19.51
-0.50 (-2.50 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CDXS News and Ratings via Email

Sign-up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Codexis (NASDAQ:CDXS) Frequently Asked Questions

Is Codexis a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Codexis stock.
View analyst ratings for Codexis
or view top-rated stocks.

What stocks does MarketBeat like better than Codexis?

Wall Street analysts have given Codexis a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Codexis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Codexis' next earnings date?

Codexis is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Codexis
.

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) posted its earnings results on Thursday, February, 25th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.07. Codexis had a negative trailing twelve-month return on equity of 21.25% and a negative net margin of 31.08%.
View Codexis' earnings history
.

How has Codexis' stock been impacted by Coronavirus (COVID-19)?

Codexis' stock was trading at $10.12 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CDXS stock has increased by 92.8% and is now trading at $19.51.
View which stocks have been most impacted by COVID-19
.

What guidance has Codexis issued on next quarter's earnings?

Codexis updated its FY 2021 After-Hours earnings guidance on Thursday, February, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $82-85 million, compared to the consensus revenue estimate of $80.53 million.

What price target have analysts set for CDXS?

4 brokers have issued 12 month price targets for Codexis' stock. Their forecasts range from $16.00 to $30.00. On average, they anticipate Codexis' share price to reach $25.25 in the next year. This suggests a possible upside of 29.4% from the stock's current price.
View analysts' price targets for Codexis
or view top-rated stocks among Wall Street analysts.

Who are Codexis' key executives?

Codexis' management team includes the following people:
  • Mr. John J. Nicols, Pres, CEO & Director (Age 57, Pay $1.06M)
  • Mr. Ross Taylor Jr., M.B.A., Sr. VP & CFO (Age 58, Pay $471.53k)
  • Dr. Karl A. Schoene Ph.D., Sr. VP of Devel. & Operations
  • Dr. Gjalt Huisman Ph.D., Sr. VP of Strategic Devel. & GM of Biotherapeutics
  • Mr. Rob Wilson Ph.D., Sr. VP & GM of Performance Enzymes
  • Dr. Stefan Lutz Ph.D., Sr. VP of Research
  • Mr. Robert Sato M.B.A., Ph.D., Sr. VP of Pharmaceutical Devel., Quality & Regulatory
  • Prof. Gerhard N. Mayr, Special Advisor to the Board (Age 75)
  • Dr. Davinder Singh Brar, Special Advisor to the Board (Age 69)

What is John J. Nicols' approval rating as Codexis' CEO?

25 employees have rated Codexis CEO John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among Codexis' employees.

Who are some of Codexis' key competitors?

What other stocks do shareholders of Codexis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), (CGC), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS).

What is Codexis' stock symbol?

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Who are Codexis' major shareholders?

Codexis' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (9.78%), BlackRock Inc. (7.93%), Wells Fargo & Company MN (3.91%), William Blair Investment Management LLC (3.63%), Janus Henderson Group PLC (2.40%) and Sumitomo Mitsui Trust Holdings Inc. (1.43%). Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Patrick Y Yang and Thomas R Baruch.
View institutional ownership trends for Codexis
.

Which major investors are selling Codexis stock?

CDXS stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Assenagon Asset Management S.A., Janus Henderson Group PLC, Wells Fargo & Company MN, Aviva PLC, Trigran Investments Inc., William Blair Investment Management LLC, and Overbrook Management Corp. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, Dennis P Wolf, and Thomas R Baruch.
View insider buying and selling activity for Codexis
or view top insider-selling stocks.

Which major investors are buying Codexis stock?

CDXS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Price T Rowe Associates Inc. MD, Avidity Partners Management LP, Baillie Gifford & Co., Pura Vida Investments LLC, Asymmetry Capital Management L.P., Monashee Investment Management LLC, and Nikko Asset Management Americas Inc.. Company insiders that have bought Codexis stock in the last two years include John J Nicols, and Patrick Y Yang.
View insider buying and selling activity for Codexis
or or view top insider-buying stocks.

How do I buy shares of Codexis?

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Codexis' stock price today?

One share of CDXS stock can currently be purchased for approximately $19.51.

How much money does Codexis make?

Codexis has a market capitalization of $1.16 billion and generates $68.46 million in revenue each year. The biotechnology company earns $-11,940,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis.

How many employees does Codexis have?

Codexis employs 161 workers across the globe.

What is Codexis' official website?

The official website for Codexis is www.codexis.com.

Where are Codexis' headquarters?

Codexis is headquartered at 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063.

How can I contact Codexis?

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at 650-421-8100 or via email at [email protected]


This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.